<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05054556</url>
  </required_header>
  <id_info>
    <org_study_id>Galectin14092021</org_study_id>
    <nct_id>NCT05054556</nct_id>
  </id_info>
  <brief_title>Galectin and Respiratory Weaning</brief_title>
  <acronym>Gal-3</acronym>
  <official_title>Prognostic Value of Galectin-3 for Success of Respiratory Weaning</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asklepios Neurological Clinic Bad Salzhausen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asklepios Neurological Clinic Bad Salzhausen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Galectin-3 is a biomarker for fibrotic activity. In the course of invasive ventilation,&#xD;
      fibrotic changes in the lungs may occur. The study aims to investigate whether the level of&#xD;
      galectin-3 levels correlates with clinical weaning parameters.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Galectin-3 (Gal-3) is a protein with an important role in cell-cell adhesion, cell-matrix&#xD;
      interactions, macrophage activation, angiogenesis, metastasis and apoptosis. Galectin-3 is&#xD;
      expressed in the nucleus, cytoplasm, mitochondrion, cell surface, and extracellular space.It&#xD;
      is involved in different biological processes: cell adhesion, cell activation and&#xD;
      chemoattraction, cell growth and differentiation, cell cycle, and apoptosis. Several studies&#xD;
      revealed the function of galectin-3 in cancer, inflammation and (lung) fibrosis, heart&#xD;
      disease, and stroke. Expression of galectin-3 is associated with heart failure, including&#xD;
      myofibroblast proliferation, fibrogenesis, tissue repair, inflammation, and ventricular&#xD;
      remodeling. A correlation between galectin-3 expression levels and various types of fibrosis&#xD;
      has been found. Galectin-3 is upregulated in idiopathic pulmonary fibrosis.&#xD;
&#xD;
      Mechanical ventilation can cause lung damage, or worsen it if already present. This&#xD;
      phenomenon is called ventilation-induced lung damage. Main mechanisms are high tidal volumes&#xD;
      causing overexpansion of the lungs (volutrauma), high airway pressure (barotrauma) and&#xD;
      cyclical collapse and reopening of atelectatic alveolar regions (atelectrauma) leading to a&#xD;
      pulmonary inflammatory reaction called &quot;bio-trauma&quot;.&#xD;
&#xD;
      To evaluate the (potential) lung injury serum levels of galectin-3 are measured on admission&#xD;
      to our hospital. During respiratory weaning invasiveness of ventilation will be reduced. Data&#xD;
      relating biomarkers especially galectin3 during/after successful respiratory weaning are&#xD;
      missing.&#xD;
&#xD;
      This is why follow up measurements of galectin-3 will be done and correlated with ventilation&#xD;
      parameters/duration/ success of respiratory weaning.&#xD;
&#xD;
      Prior studies evaluated the role of proGRP and CA 15-3 in patients with lung fibrosis. As a&#xD;
      part of the study galectin-3 serum levels will be correlated with serum levels of proGRP and&#xD;
      CA 15-3.&#xD;
&#xD;
      In summary the aim of this study is to evaluate the diagnostic value of galectin-3 in&#xD;
      respiratory weaning.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To correlate the serum levels of galectin-3 and duration of respiratory weaning.</measure>
    <time_frame>2-3 months</time_frame>
    <description>Labaratory test+Clinical data.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum levels of galectin-3 on admission, after weaning and discharge from hospital. Correlation of: galectin-3 and duration of respiratory weaning invasiveness of ventilation parameters and galectin-3 serum levels of galectin-3, proGRP and CA 15-3.</measure>
    <time_frame>2-3 months</time_frame>
    <description>Clinical data, labaratory tests.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Galectin-3 During Respiratory Weaning</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Labaratory tests</intervention_name>
    <description>Estimation of serum levels of the following parameters:&#xD;
galectin-3, proBNP, TNI, proGRP, CA15-3, CK, creatinine, urea, crp, pct, leucozytes</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with mechanical ventilation who are admitted to our hospital for respiratory&#xD;
        weaning.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
          -  mechanical ventilation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of pulmonary disease&#xD;
&#xD;
          -  left ventricular ejection fraction&lt;45%&#xD;
&#xD;
          -  missing declaration of consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dirk Bandorski, MD</last_name>
    <phone>+496043804212</phone>
    <email>d.bandorski@asklepios.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Neurologische Klinik Bad Salzhausen</name>
      <address>
        <city>Nidda</city>
        <zip>63667</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 14, 2021</study_first_submitted>
  <study_first_submitted_qc>September 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2021</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

